I
n patients with Barrett esophagus or Barrett mucosa, metaplastic columnar epithelium replaces the normal squamous epithelium in the distal esophagus. This condition develops in approximately 10 -15% of patients with chronic gastroesophageal reflux.
1,2 Barrett esophagus is the major recognized risk factor for esophageal adenocarcinoma, and patients have a 30 -40-fold increased risk of developing malignant disease compared with the general population. 3, 4 The incidence of adenocarcinoma of the esophagus has been increasing steadily in the United States for the last 20 years, with the incidence in white males growing by Ͼ 350% over that time period. 5 Aggressive medical management of acid reflux, lifestyle modifications, laser ablation, and endoscopic surveillance have been recommended for many patients with Barrett esophagus. 6 -8 Whether these interventions are cost-effective or reduce mortality from esophageal cancer remains controversial. 9 Dysplasia in Barrett esophagus is an intraepithelial neoplasia and the primary predictor of progression to adenocarcinoma. 10 Highgrade dysplasia (HGD) in Barrett esophagus frequently undergoes malignant transformation and is associated with a high rate of occult malignancy. For this reason, many patients with HGD undergo esophageal resection. 11, 12 Limited data are available for elucidating the rate at which low-grade dysplasia (LGD) progresses to HGD or carcinoma. Some studies suggest that the rate ranges from 10% to 30% over 5 years. [13] [14] [15] [16] Due to the increased risk of malignant disease and the lack of good treatment options for LGD in Barrett esophagus, a randomized chemoprevention trial was recently performed in which difluoromethylornithine (DFMO) was given to individuals with Barrett esophagus who either had LGD or did not exhibit dysplasia. 17 In that study, in which a single pathologist reviewed every case, the number of patients identified and enrolled was exceedingly small (LGD: n ϭ 2; negative for dysplasia: n ϭ 77). This finding was unexpected, as the prevalence of dysplasia reported in the literature is highly variable. 13,18 -25 One study reported LGD in as many as 70.8% of patients with Barrett esophagus. 18 This variability in prevalence rates represents a challenge in designing and implementing randomized chemoprevention studies. In the current study, we searched within a small multiinstitutional consortium to retrospectively identify individuals with dysplasia in Barrett esophagus who would be available for enrollment in a chemoprevention trial.
MATERIALS AND METHODS

Study Design and Population
A retrospective review of the pathology archives of the University of Michigan (Ann Arbor, MI), Henry Ford Hospital (Detroit, MI), and Brigham and Women's Hospital (Boston, MA) over a 5-year period was performed to identify all cases of Barrett esophagus. Reports of specimens that were obtained from biopsies and resections above the gastroesophageal junction and reported as either intestinal-type Barrett esophagus, specialized-type Barrett esophagus, or specialized-type columnar epithelium were included in the analysis. No pathology specimens or slides were pulled for review.
After obtaining institutional review board exemption, pathology reports from the University of Michigan over the period 1995-1999 were reviewed for eligibility. Original identifiers for patients were used initially to identify duplicate reports. Case numbers were subsequently assigned, and all identifiers were then removed. If there were duplicate reports for any one case, then the most advanced diagnosis was used. When there were multiple reports with the same diagnosis, the earliest diagnosis was used. The data recorded from each report included the type of Barrett esophagus (negative for dysplasia, indefinite for dysplasia, LGD, and HGD), age, gender, whether the specimen was obtained after a biopsy or a resection, and the year of the report. Additional information included the pathologist to whom the case was referred, the physician who wrote the official report, the five-digit accession number, and the hospital registration number. Reports with any findings of cancer, surgically resected cases, and referral cases were removed before analysis.
Data from Henry Ford Hospital included the period between 1996 and the first 3 months of 2000. Data from Brigham and Women's Hospital were collected for the period 1995-1999. Data were collected and handled at both institutions in the same manner as at the University of Michigan.
Cases of Barrett esophagus were summarized by degree of dysplasia, institution of origin, and year of diagnosis. Differences among institutions in the proportion of cases by degree of dysplasia were tested using the standard Pearson chi-square statistic. Comparisons of case characteristics between types of dysplasia were made using the two-sample t test and the chi-square statistic when appropriate. Two-sided P values Ͻ 0.05 were considered to be statistically significant.
Definition of Outcome
Barrett esophagus was diagnosed if metaplastic columnar epithelium was observed in biopsy specimens obtained from the tubular esophagus above the gastroesophageal junction. Dysplasia was defined as neoplastic epithelium that was not invasive. Cytologic changes included nuclear enlargement, hyperchromatism, pleomorphism and stratification, atypical-appearing mitoses, and loss of cytoplasmic maturation. Architectural changes included crowding of tubules and/or villiform surfaces. 26 LGD was characterized by these changes occurring with a relatively low level of intensity and by more closely caricatured nonneoplastic epithelium, whereas HGD was characterized by more intense changes. If the biopsy specimen had morphologic changes that were not clearly dysplastic but also not clearly reactive, then the biopsy specimen was considered to be indefinite for dysplasia.
RESULTS
Among the 3 institutions involved in the study, 790 cases of Barrett esophagus met the study criteria. Case characteristics are shown in Table 1 . Seventy percent of the cases who were negative for dysplasia were male, and 30% were female. Males accounted for 78% of LGD cases and 90% of HGD cases. The mean age of cases who were negative for dysplasia was 57.8 Ϯ 13.8 years, the mean age of cases with LGD was 62.9 Ϯ 12.7 years, and the mean age of cases with HGD was 67.3 Ϯ 12.8 years. The mean age of cases with HGD was statistically different from the mean age of cases who were negative for dysplasia (P ϭ 0.004).
Of the 790 cases identified, 360 were from the University of Michigan, 191 were from Henry Ford Hospital, and 239 were from Brigham and Women's Hospital (Table 2) . When all institutions were combined, negative for dysplasia accounted for 686 cases, indefinite for dysplasia accounted for 47 cases, LGD accounted for 37 cases, and HGD accounted for 20 cases. At the University of Michigan, Henry Ford Hospital, and Brigham and Women's Hospital, LGD represented 5.0%, 7.9%, and 1.7% of all Barrett esophagus cases, respectively. The difference between Henry Ford Hospital and Brigham and Women's Hospital was statistically significant (P ϭ 0.004). None of the rates for other dysplasia types were statistically different across institutions. Table 3 shows the distribution of the types of Barrett esophagus by year. For all institutions, the number of cases that were negative for dysplasia ranged from 118 to 174 per year, the number of cases that were indefinite for dysplasia ranged from 8 to 11 per year, the number of LGD cases ranged from 5 to 12 per year, and the number of HGD cases ranged from 2 to 6 per year.
DISCUSSION
The current multiinstitutional review supports the finding that few individuals with dysplasia in Barrett esophagus are available for enrollment in chemoprevention trials. 17 Dysplasia in Barrett esophagus is a premalignant condition that has been the focus of attention for esophageal adenocarcinoma prevention strategies and remains the primary predictor of malignant progression. 10 However, the limited number of individuals with LGD has ramifications for those committed to the clinical study of Barrett esophagus.
Variable rates of dysplasia in the literature have made the design of clinical chemoprevention trials challenging (Table 4) . 13,18 -25 Several single-institution studies have attempted to directly measure the prevalence and/or incidence of dysplasia in Barrett esophagus. 19 -21,24 Those institutions report LGD in 7.9 -25.9% of cases of Barrett esophagus. Gopal et al. 22 recently published a prospective multiinstitutional study that attempted to determine risk factors for dysplasia. In that study, LGD was diagnosed in 9.4% of all Barrett esophagus cases. Although the study conducted by Gopal et al. was multiinstitutional, 75% of all cases were diagnosed at a Veterans Administration hospital, and thus the study population is not likely to have been representative of the population of individuals with Barrett esophagus in the United States. Most of the reported case series are from surveillance programs, which can best determine the number of incident (newly diagnosed) cases of dysplasia. However, identification of all cases by review of pathology records mimics clinical trial recruitment and provides a better measure of prevalent cases and potential participants available for chemopreventive interventions. The current analysis, in which cases were identified by pathology review, involves an unselected cohort of cases of LGD in Barrett esophagus diagnosed at three institutions serving diverse populations.
The variability across studies is primarily a reflection of problems with the diagnosis of dysplasia. Despite attempts at establishing criteria for the diagnosis of dysplasia in Barrett esophagus in 1988 27 and attempts at refinement of those criteria in 2001, 28 confirmation of the diagnosis remains a significant challenge. Several studies have reported that LGD was not confirmed in approximately 75% of patients. 20, 21, 23 Even among experienced pathologists, the interobserver agreement for the diagnosis of LGD is only 50%. 27, 28 In the current study, more than three pathologists across the three institutions were involved in reporting LGD. However, results from our recent multiinstitutional clinical trial, in which a central pathologist reviewed all cases, were consistent with the results of the current analysis (2.6% LGD; unpublished data). Combining the indefinite for dysplasia and LGD categories improves the concordance among pathologists. As a result, some have chosen to combine these diagnoses when reporting rates. 13, 24, 27 In the current study, the combined percentage of indefinite/LGD cases was 10.6%. Diagnostic problems will be lessened by the further development of biomarkers that can better predict which individuals will experience progression to invasive malignancy. 29 -31 However, until that time, difficulties with the pathologic diagnosis will continue to represent a challenge in chemoprevention studies.
Variations in environmental influences and risk groups of Barrett esophagus across the country might also result in differences in the rates of dysplasia that are reported. Limited information is provided in other studies with regard to population characteristics. However, variation in esophageal adenocarcinoma incidence across the country supports the likelihood of regional variation in the occurrence of dysplasia. 32 In addition, although the columnar epithelium of Barrett mucosa can have a distinctive red hue and velvety texture, dysplasia has no obvious appearance. Thus, sampling error is prominent due to the requirement of random biopsies in standard endoscopic procedures. 33 Sampling error and spontaneous regression are likely contributors to the difficulty of confirming the diagnosis of LGD in surveillance series. 20, 21, 23 More rigorous biopsy techniques, as used for HGD surveillance, 14 ,33 may lead to more accurate measures of LGD prevalence, but currently, these techniques are not used routinely for Barrett esophagus or LGD surveillance.
In the current analysis, we used the most advanced diagnosis for each individual. Four cases of LGD were not counted because their diagnoses preceded more advanced diagnoses (i.e., HGD or malignant disease). Consequently, the number of LGD cases may have been underestimated to a small degree. Referral bias is a major concern in reporting prevalence estimates in Barrett esophagus, particularly at large tertiary medical centers. Exclusion of patients referred from extramural physicians for pathologic review limited referral bias, resulting in a more accurate reflection of the number of individuals with dysplasia who would be treated at each institution. Surgical specimens also were excluded, because many patients who undergo surgery represent referral cases. These individuals would also not be available for chemopreventive interventions. However, many individuals with diagnoses of LGD or indefinite for dysplasia undergo follow-up with community gastroenterologists. Therefore, the rates reported from tertiary care centers might not reflect the true prevalence of dysplasia within a given population.
Poor recruitment rates in chemoprevention trials underscore the importance of accurately determining the number of potential participants. The ratio of potential participants screened for enrollment to those who are actually enrolled varies markedly, ranging from 7:1 to Ͼ 100:1.
17,34 Our recent randomized efficacy trial for a putative chemoprevention agent (i.e., DFMO) required 76 participants per arm to detect a designed morphologic regression or biomarker modulation. 17 With a screened-to-on-study ratio of 15:1, as encountered in this study, 17 2280 (i.e., 15 ϫ 152) otherwise eligible participants would be required. Our intent in performing the current analysis was to determine the recruitment cohort size necessary to study the efficacy of a chemopreventive intervention in a randomized design. Due to the documented low rate of LGD and the poor screened-to-on-study ratio, the screening of such a population would require the collaboration of the bulk of the institutions in the United States to successfully identify, recruit, and retain the necessary number of study participants.
We believe that the current analysis estimates the number of individuals with LGD in Barrett esophagus who are available for chemoprevention studies more accurately than do previous reports. Based on our findings, alternative clinical trial designs will be required to effectively study chemopreventive interventions for patients with Barrett esophagus.
